- Home
- EIX vs RPRX Comparison
EIX vs RPRX Comparison
Compare EIX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIX
- RPRX
- Stock Information
- Founded
- EIX 1886
- RPRX 1996
- Country
- EIX United States
- RPRX United States
- Employees
- EIX N/A
- RPRX N/A
- Industry
- EIX Electric Utilities: Central
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- EIX Utilities
- RPRX Health Care
- Exchange
- EIX Nasdaq
- RPRX Nasdaq
- Market Cap
- EIX 21.3B
- RPRX 16.2B
- IPO Year
- EIX N/A
- RPRX 2020
- Fundamental
- Price
- EIX $56.78
- RPRX $40.88
- Analyst Decision
- EIX Hold
- RPRX Strong Buy
- Analyst Count
- EIX 12
- RPRX 3
- Target Price
- EIX $65.27
- RPRX $46.00
- AVG Volume (30 Days)
- EIX 2.9M
- RPRX 2.9M
- Earning Date
- EIX 10-28-2025
- RPRX 11-05-2025
- Dividend Yield
- EIX 5.85%
- RPRX 2.16%
- EPS Growth
- EIX 123.49
- RPRX N/A
- EPS
- EIX 7.64
- RPRX 1.60
- Revenue
- EIX $18,088,000,000.00
- RPRX $2,349,553,000.00
- Revenue This Year
- EIX $7.30
- RPRX $36.16
- Revenue Next Year
- EIX $2.70
- RPRX $2.04
- P/E Ratio
- EIX $7.41
- RPRX $25.42
- Revenue Growth
- EIX 4.43
- RPRX 3.69
- 52 Week Low
- EIX $47.73
- RPRX $24.05
- 52 Week High
- EIX $88.65
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- EIX 54.92
- RPRX 75.93
- Support Level
- EIX $53.56
- RPRX $36.03
- Resistance Level
- EIX $58.73
- RPRX $37.40
- Average True Range (ATR)
- EIX 1.18
- RPRX 1.11
- MACD
- EIX -0.07
- RPRX 0.38
- Stochastic Oscillator
- EIX 61.24
- RPRX 93.15
About EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.